Who is a Candidate for Watch and Wait Therapy in Mantle Cell Lymphoma?

被引：1

作者：

Kumar, Anita ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

indolent biology; mantle cell lymphoma; MCL; observation; survival; TP53; mutation; SURVIVAL;

D O I：

10.1016/j.clml.2019.07.437

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EXABS-MCL-

引用

页码：S109 / S111

页数：3

共 10 条

[1] Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study
Abrahamsson, Anna
Albertsson-Lindblad, Alexandra
Brown, Peter N.
Baumgartner-Wennerholm, Stefanie
Pedersen, Lars M.
D'Amore, Francesco
Nilsson-Ehle, Herman
Jensen, Paw
Pedersen, Michael
Geisler, Christian H.
Jerkeman, Mats
[J]. BLOOD, 2014, 124 (08) : 1288 - 1295
[2] Observation as the initial management strategy in patients with mantle cell lymphoma
Abrisqueta, P.
Scott, D. W.
Slack, G. W.
Steidl, C.
Mottok, A.
Gascoyne, R. D.
Connors, J. M.
Sehn, L. H.
Savage, K. J.
Gerrie, A. S.
Villa, D.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2489 - 2495
[3] Clot G, 2018, BLOOD
[4] Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma
Cohen, Jonathon B.
Han, Xuesong
Jemal, Ahmedin
Ward, Elizabeth M.
Flowers, Christopher R.
[J]. CANCER, 2016, 122 (15) : 2356 - 2363
[5] TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Eskelund, Christian W.
Dahl, Christina
Hansen, Jakob W.
Westman, Maj
Kolstad, Arne
Pedersen, Lone B.
Montano-Almendras, Carmen P.
Husby, Simon
Freiburghaus, Catja
Ek, Sara
Pedersen, Anja
Niemann, Carsten
Raty, Riikka
Brown, Peter
Geisler, Christian H.
Andersen, Mette K.
Guldberg, Per
Jerkeman, Mats
Gronbaek, Kirsten
[J]. BLOOD, 2017, 130 (17) : 1903 - 1910
[6] Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Martin, Peter
Chadburn, Amy
Christos, Paul
Weil, Karen
Furman, Richard R.
Ruan, Jia
Elstrom, Rebecca
Niesvizky, Ruben
Ely, Scott
DiLiberto, Maurizio
Melnick, Ari
Knowles, Daniel M.
Chen-Kiang, Selina
Coleman, Morton
Leonard, John P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1209 - 1213
[7] Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis
Ondrejka, Sarah L.
Lai, Raymond
Smith, Stephen D.
Hsi, Eric D.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (08): : 1121 - 1127
[8] The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Rosenwald, A
Wright, G
Wiestner, A
Chan, WC
Connors, JM
Campo, E
Gascoyne, RD
Grogan, TM
Muller-Hermelink, HK
Smeland, EB
Chiorazzi, M
Giltnane, JM
Hurt, EM
Zhao, H
Averett, L
Henrickson, S
Yang, LM
Powell, J
Wilson, WH
Jaffe, ES
Simon, R
Klausner, RD
Montserrat, E
Bosch, F
Greiner, TC
Weisenburger, DD
Sanger, WG
Dave, BJ
Lynch, JC
Vose, J
Armitage, JO
Fisher, RI
Miller, TP
LeBlanc, M
Ott, G
Kvaloy, S
Holte, H
Delabie, J
Staudt, LM
[J]. CANCER CELL, 2003, 3 (02) : 185 - 197
[9] Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease
Royo, C.
Navarro, A.
Clot, G.
Salaverria, I.
Gine, E.
Jares, P.
Colomer, D.
Wiestner, A.
Wilson, W. H.
Vegliante, M. C.
Fernandez, V.
Hartmann, E. M.
Trim, N.
Erber, W. N.
Swerdlow, S. H.
Klapper, W.
Dyer, M. J. S.
Vargas-Pabon, M.
Ott, G.
Rosenwald, A.
Siebert, R.
Lopez-Guillermo, A.
Campo, E.
Bea, S.
[J]. LEUKEMIA, 2012, 26 (08) : 1895 - 1898
[10] Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas:: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial
Solal-Céligny, P
Lepage, E
Brousse, N
Tendler, CL
Brice, P
Haïoun, C
Gabarre, J
Pignon, B
Tertian, G
Bouabdallah, R
Rossi, JF
Doyen, C
Coiffier, B
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2332 - 2338

← 1 →